Boxer Capital

Boxer Capital

Boxer Capital

Tavistock Group is an international private investment organization founded by Joe Lewis more than 40 years ago and built on a core philosophy: We strive for excellence in everything we do.
Follow us
$85,000,000 Venture capital (Series C)
FinSMEs , GeekWire

Silverback Therapeutics Raises $85M in Series C Financing

ChinaMoneyNetwork

Connect Biopharmaceuticals Raises $115M Series C Round – China Money Network

ChinaMoneyNetwork

Connect Biopharmaceuticals Raises $115M Series C Round – China Money Network

$115,000,000 Venture capital (Series C)
Pulse 2.0 , FinSMEs

Clinical-Stage Biopharmaceutical Company Connect Biopharma Raises $115 Million

Pulse 2.0

Targeted Cancer Therapy Biotech Company Tango Therapeutics Raises $50 Million 

Xconomy

Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor

$50,000,000 Venture capital
FinSMEs

Tango Therapeutics Raises $50M in Equity Financing

$135,000,000 Venture capital (Series D)
FinSMEs , Pulse 2.0

Encoded Therapeutics Raises $135M in Series D Financing

$72,500,000 Venture capital (Series D)
FinSMEs

BioAtla Raises $72.5M In Series D Financing

neurons.AI

Global Superoxide Dismutase Cu-Zn Market 2020 – AveXis Inc , Ionis Pharmaceuticals Inc …

$110,000,000 Venture capital (Series D)
FinSMEs

Poseida Therapeutics Raises $110M in Series D Financing

$60,000,000 Venture capital (Series B)
Pulse 2.0

Targeted Cancer Therapies Company Tango Closes $60 Million

Xconomy

Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug

FinSMEs

Silverback Therapeutics Raises $78.5M in Series B Financing

$50,000,000 Venture capital (Series A)
FinSMEs

Tyra Biosciences Raises USD 50M in Series A Funding

the home of AI info

Global Superoxide Dismutase [Cu-Zn] Market 2016-2026 | AveXis Inc, Ionis Pharmaceuticals Inc ...

Technical.ly Philly

University City biotech firm Cabaletta Bio Inc. goes public in $74.8M IPO

PE HUB

VC-backed Cabaletta Bio begins trading on NASDAQ

$113,800,000 IPO
PE HUB

Biopharma firm Atreca goes public

$50,000,000 Venture capital (Series B)
MedCity News , FinSMEs

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies